For media enquiries about any aspect of the work of the PMCPA please contact the Press Office Direct: 02077478884 Mobile: 07920863650 email@example.com Sign up for eAlerts at the top of the page Follow us on Twitter @PMCPAUK
The PMCPA publishes certain Sanctions (advertisements, public reprimands and corrective statements) Press Releases, Case Reports and Code of Practice Reviews.
- the carrying out by the PMCPA of an audit of a company’s procedures to comply with the Code. This can also be followed by a requirement that promotional material be submitted to the PMCPA for pre-vetting for a specified period
- requiring the company to take steps to recover items from those to whom they have been given
- requiring the company to issue a corrective statement
- a public reprimand
- suspension or expulsion from membership of the ABPI.
Where companies are ruled in breach of Clause 2 of the Code, and/or are required to issue a corrective statement and/or are the subject of a public reprimand, the PMCPA advertises brief details of the cases in the medical, nursing and pharmaceutical press, the advertisements are also published on this website.
Case Reports (access Case Reports here)
As mentioned above, in some cases a company may be required to issue a corrective statement or may be the subject of a public reprimand or advertisements in the medical and pharmaceutical press.Code of Practice Review (access Code of Practice Reviews here)
The Code of Practice Review is published quarterly by the PMCPA. It includes the case reports of all cases completed within the previous three months, new advice that has been issued on the Code and an editorial relating to current matters of interest.
Daiichi-Sankyo, GW Pharmaceuticals, Bayer plc, Proveca Ltd, Otsuka UK & Otsuka Europe named in advertisements
27 July 2019read more
The MHRA has issued guidance regarding the process for the conversion of centrally approved products (CAPs) to UK marketing authorizations in relation to preparation in the event of the UK leaving the EU with no deal.
10 April 2019read more
Sunovion Pharmaceuticals Europe Ltd and Shield Therapeutics will be named in advertisements(1) following breaches of the ABPI Code of Practice for the Pharmaceutical Industry. The companies have brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition Sunovion was publicly reprimanded.
17 December 2018read more
Astellas Pharmaceuticals Limited will be named in advertisements(1) following breaches of the ABPI Code of Practice for the Pharmaceutical Industry. The company has brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition Astellas UK has been publicly reprimanded.
17 December 2018read more
Disclosure template for 2018 data submissions
10 December 2018read more
Proposals to amend the ABPI Code of Practice 2016 and the PMCPA Constitution and Procedure were agreed by ABPI members on 4 December 2018.
06 December 2018read more